Where is Edity located?

Edity is headquartered in Rehovot, Israel.

Who is the current CEO of Edity?

Michal Golan Mashiach of Edity. They have also founded 1 company.

How many employees does Edity have?

As of May 31, 2026, the latest employee count at Edity is 23.

Is Edity a funded company?

Edity is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Edity rank among its competitors?

Edity ranks 101st amongst 123 active competitors, of which 45 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Enlivex Pharmaceuticals, which secured $212M in Nov, 2025.

Who are the top competitors of Edity?

Edity's top competitors include Genedit, Enlivex Pharmaceuticals and Sernova. Among them, Enlivex Pharmaceuticals secured the most recent funding round in November, 2025.

Edity - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of a drug delivery platform based on gene-editing technology. It offers a platform that uses immune cells to transfer therapeutic proteins to the cytoplasm of target cells to reprogram cells and tissue.

Website: edity-tx.com
Email ID: *****@edity-tx.com
Phone Number: +972 **********

Key Metrics

Founded Year

2020

Location

Rehovot, Israel

Stage

Funding Raised

Investors

NFX & 2 more

Ranked

101^st among 123 active competitors

Employee Count

23 as on May 31, 2026

Similar Companies

Genedit & 155 more

View Edity's full profile

Edity is a funded company. Edity has 2 institutional investors and 1 angel investor.

View details of Edity's funding rounds and investors

The founders of Edity are Yoav Manaster and Michal Golan Mashiach. Michal Golan Mashiach is the CEO of Edity.

Here are the details of Edity's key team members:

Yoav Manaster: Co-Founder of Edity and founder of 1 other company.
Contact Info: 1 email address
Michal Golan Mashiach: Founder & CEO of Edity.

View details of Edity's Founder profiles and Board Members

Edity's employee count trend

Edity has 23 employees as of May 26. Here is Edity's employee count trend over the years:

Uncover Edity's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Edity include Genedit, Enlivex Pharmaceuticals and Sernova. Here is the list of Top 10 competitors of Edity, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Genedit 2016, Berkeley (United States), Series B	Developer of drug delivery system for genetic medicines	$93.5M	IMM Investment, SK & 20 others	64/100
2nd	Enlivex Pharmaceuticals 2005, Jerusalem (Israel), Public	Developer of autologous and allogeneic cell immunotherapy therapy treatments	$7M	Pontifax, Korea Investment Holdings & 2 others	62/100
3rd	Sernova 1998, London (Canada), Public	Regenerative medicine to deliver proteins and hormones for disease treatment	-	National Research Council Canada, Europa & 1 others	61/100
4th	LogicBio 2013, Lexington (United States), Acquired	Developer of viral vectors for the treatment of genetic and infectious diseases	$49M	Arix Bioscience, Andera Partners & 6 others	60/100
5th	Genenta Science 2014, Milan (Italy), Public	Developer of lentivirus-based gene and cell therapies for cancer	$33.6M	Mediobanca, Qianzhan & 3 others	58/100
6th	Candel Therapeutics 1999, United States, Public	Developer of viral immunotherapies for the treatment of cancer	$81.6M	PBM Capital, B. Riley Wealth Management & 4 others	57/100
7th	Orgenesis 2008, Germantown (United States), Public	Developer of cell and gene therapies for multiple disorders	-	Kodiak Capital, Metalmark Capital & 4 others	55/100
8th	SonoThera 2022, San Francisco (United States), Series A	Developer of nonviral gene therapies for genetic diseases	$60.8M	Arch Venture Partners, Lilly & 9 others	55/100
9th	TissueGene 1999, Rockville (United States), Series C	Developer of regenerative therapies for orthopedic diseases	$94.6M	Q Capital Partners, Maryland Stem Cell Research Fund ... Read more	55/100
10th	ExpreS2ion Biotechnologies 2010, Copenhagen (Denmark), Public	Provider of recombinant protein production using an insect expression platform	-	Modelio Equity, Gemstone Capital & 2 others	53/100
101st	Edity 2020, Rehovot (Israel), Funding Raised	Developer of a drug delivery platform based on gene-editing technology	-	NFX, Tal Ventures & 1 others	26/100